Non-alcoholic fatty liver disease: Natural history, pathogenesis and treatment

British Journal of Diabetes and Vascular Disease

Volumn 6, Issue 6, 2006, Pages 251-260

  McAvoy, Norma C ^a   Ferguson, James W ^b   Campbell, Ian W ^b   Hayes, Peter C ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b VICTORIA HOSPITAL   (United Kingdom)

Author keywords

Cirrhosis; Diabetes; Metabolic; Obesity

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; ANTIBIOTIC AGENT; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN SENSITIZING AGENT; LEPTIN; LOSARTAN; METFORMIN; PENTOXIFYLLINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PIOGLITAZONE; PLACEBO; PROBIOTIC AGENT; REACTIVE OXYGEN METABOLITE; RIMONABANT; ROSIGLITAZONE; S ADENOSYLMETHIONINE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; URSODEOXYCHOLIC ACID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL LIVER DISEASE; BARIATRIC SURGERY; BLOOD PRESSURE REGULATION; BYPASS SURGERY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; DIET THERAPY; DIETARY INTAKE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENVIRONMENTAL FACTOR; GENETIC SUSCEPTIBILITY; GLUCOSE HOMEOSTASIS; HISTOPATHOLOGY; HUMAN; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPID METABOLISM; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FUNCTION TEST; LIVER TOXICITY; METABOLIC SYNDROME X; MONOTHERAPY; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PREVALENCE; REVIEW; RISK FACTOR; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 33846299876     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514060060060201     Document Type: Review

References (73)

1. Jimba S, Nakagami T, Takahashi M et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med 2005;22:1141-5.
2. Bedogni G, Miglioli L, Masutti F et al. Prevalence of and risk factors for non-alcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005;42:44-52.
3. Ruhl CE, Everhart JE. Epidemiology of nonalcoholic fatty liver. Clin Liver Dis 2004;3:501-19vii.
4. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-9.
5. Nomura H, Kashiwagi S, Hayashi J et al. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 1988;27:142-9.
6. Colicchio P, Tarantino G, del Genio F et al. Non alcoholic fatty liver disease in young adult severely obese non-diabetic patients in South Italy. Ann Nutr Metab 2005;49:289-95.
7. Lima ML, Mourao SC, Diniz MT, Leite VH. Hepatic histopathology of patients with morbid obesity submitted to gastric bypass. Obes Surg 2005;15:661-9.
8. Angelico F, Del Ben M, Conti R et al. Insulin resistance, the metabolic syndrome and nonalcoholic fatty liver disease. J Clin Endocrinol & Metabol 2005;90:1578-82.
9. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults 2001 Executive summary, of the Third Report of the National Cholesterol Education program (VCEP). Expert panel on Detection, Evaluation and Treatment of High Cholesterol in Adults (Adult Treatment Panel III). JAMA 285;2:484-97.
10. Ratziu V, Charlotte F, Heurtier A et al. Sampling variability of liver biopsy in non alcoholic fatty liver disease. Gastroenterology 2005;128:1898-906.
11. Thomas EL, Hamilton G, Patel N. Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study. Gut 2005;54:122-7.
12. Mofrad P, Contos MJ, Haque M et al. Clinical and histological spectrum of non alcoholic fatty liver disease associated with normal ALT values. Hepatology 2003;37:1286-92.
13. Younossi ZM, Gramlich T, Matteoni CA et al. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol 2004; 2:262-5.
14. Loria P, Lonardo A, Leonardi F et al. Non-organ-specific autoantibodies in non-alcoholic fatty liver: prevalence and correlates. Did Dis Sci 2003;48: 2173-81.
15. Adams LA, Sanderson S, Lindor KD et al. The histological course of non alcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005;42:132-8.
16. Day CP, James OFW. Steatohepatitis: a tale of two 'hits'. Gastroenterology 1998; 114:842-5.
17. Cortez-Pinto. Concluding remarks: metabolic syndrome, liver and HCV. Aliment Pharmacol Ther 2005;22(suppl 2):83-5.
18. Dreimane D, Kaufman F. Childhood NAFLD as currently reported: differentiating simple steatosis from NASH is possible with liver biopsy data. In: Atlas of Clinical Endocrinology: Diabetes (Ed. Jay S Skyler) 2006 Current Medicine Inc.
19. Marrero JA, Fontana RJ, Fu S et al. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol 2005;42:218-24.
20. Hashimoto E, Yatsuji S, Kaneda H et al. The characteristics and natural history of Japanese patients with nonalcoholic fatty liver disease. Hepat Res 2005;33:72-6.
21. Adams LA, Lymp JF, St Sauver J et al. The natural history of non alcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-21.
22. Marchesini G, Brizi M, Bianchi G et al. Non-alcoholic fatty liver disease. A feature of the metabolic syndrome. Diabetes 2001;50:1844-50.
23. Donati G, Stagni B, Piscaglia F et al. Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut 2004;53:1020-3.
24. Kim JK, Fillmore JJ, Chen Y et al. Tissue specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci USA 2001;98:7522-7.
25. Sanyal AJ, Campbell-Sargent C, Mirshahi F et al. Non-alcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-92.
26. Bugianesi E, Manzini P, D'Antico S et al. Relative contribution of iron burden, HFE mutations and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 2004;39:179-87.
27. Pagano G, Pacini G, Musso G et al. Nonalcoholic steatohepatitis, insulin resistance, metabolic syndrome: further evidence for an etiologic association. Hepatology 2002;35:365-72.
28. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 2000; 106:171-6.
29. Hotamisligil GS, Peraldi SP, Budavari A et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996;271:665-8.
30. Pessayre D, Fromenty B. NASH: a mitochondrial disease. J Hepatol 2005; 42:928-40.
31. Ip E, Farrell G, Hall P et al. Administration of the potent PPARα agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology 2004;39:1286-96.
32. Namikawa C, Shu-Ping Z, Vyselaar JR et al. Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. J Hepatol 2004;40:781-6.
33. Perez-Carreras M, Del Hoyo P, Martin MA et al. Defective hepatic mitochondrial respiratory chain in patients with non alcoholic steatohepatitis. J Hepatol 2003;38:999-1007.
34. Ibhad JA, Perlegas P, Zhao Y et al. Mice Heterozygous for a Defect in Mitochondrial Trifunctional Protein Develop Hepatic Steatosis and Insulin Resistance. Gastroenterology 2005;128:1381-90.
35. Kim JK, Kim Y-J, Fillmore JJ et al. Prevention of fat induced insulin resistance by salicylate. J Clin Invest 2001;108:437-46.
36. Crespo J, Cayon A, Fernandez-Gil P et al. Gene expression of tumour necrosis factor alpha and TNF-receptors, p55 and p75, in non alcoholic steatohepatitis patients. J Hepatol 2001; 34:1158-63.
37. Yamauchi T, Kamon J, Minokoshi Y et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8:1288-95.
38. Hui JM, Hodge A, Farrell GC et al. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004;40:46-54.
39. Tilg H, Wolf AM. Adiponectin: a key fat-derived molecule regulating inflammation. Expert Opin Ther Targets 2005;9:245-51.
40. Xu A, Wang Y, Kershaw H et al. The fat derived hormone adiponectin alleviates alcoholic and non-alcoholic fatty liver diseases in mice. J Clin Invest 2003;112:91-100.
41. Chitturi S, Farrell G, Frost L et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? J Hepatol 2002;36:403-09.
42. Saxena NK, Ikeda K, Rockey DC et al. Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. J Hepatol 2002;35:761-71.
43. Pagano C, Soardo G, Pilon C et al. Increased serum resistin in non-alcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J Clin Endocrin Metabol 2006;10:1210.
44. Chen MP, Chung FM, Chang DM et al. Elevated plasma level of visfatin/ pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006;91:295-9.
45. Yesilova Z, Ozata M, Oktenli C et al. Increased acylation stimulating protein concentrations in nonalcoholic fatty liver disease are associated with insulin resistance. Am J Gastroenterol 2005;100:842-9.
46. Jang Y, Lee JH, Kim OY et al. The SNP276G>T polymorphism in the adiponectin (ACDC) gene is more strongly associated with insulin resistance and cardiovascular disease risk than SNP45T>G in nonobese/ nondiabetic Korean men independent of abdominal adiposity and circulating plasma adiponectin. Metabolism 2006;55(1):59-66.
47. Valenti L, Fracanzani AL, Dongiovanni P et al. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 2002;122:274-80.
48. Marchesini G, Forlani G, Bugianesi E. Is liver disease a threat to patients with metabolic disorders? Ann Med 2005;37:333-46.
49. Eriksson S, Eriksson KF, Bondesson L. Nonalcoholic steatohepatitis in obesity: a reversible condition. Acta Med Scand 1986;220:83-8.
50. Franzese A, Vajro P, Argenziano A et al. Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci 1997;42:1428-32.
51. Hickman IJ, Jonsson JR, Prins JB et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004;53:413-19.
52. Knobler H, Schattner A, Zhornicki T et al. Fatty liver - an additional and treatable feature of the insulin resistance syndrome. QJM 1999;92:73-9.
53. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003;38:413-19.
54. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990;99:1408-13.
55. Ueno T, Sugawara H, Sujaku K et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997;27:103-07.
56. Monzillo LU, Hamdy O, Horton ES et al. Effect of lifestyle modification on adipokine levels in obese subjects with insulin resistance. Obes Res 2003; 11:1048-54.
57. Wadden TA, Berkowitz RI, Womble LG et al. Randomized Trial of Lifestyle Modification and Pharmacotherapy for Obesity. N Engl J Med 2005;353: 2111-20.
58. Blackburn GL, Mun EC. Effects of weight loss surgeries on liver disease. Semin Liver Dis 2004;24:371-9.
59. Kiyici M, Gulten M, Gurel S et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol 2003;17:713-18.
60. Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004;126:1287-92.
61. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 2001;351:893-4.
62. Bugianesi E, Gentilcore E, Manini R et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005;100:1082-90.
63. Nair S, Diehl AM, Wiseman M, Farr GH Jr., Perrillo RP. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 2004;20:23-8.
64. Uygun A, Kadayifci A, Isik AT et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004;19:537-44.
65. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001;96:519-25.
66. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003;38:1008-17.
67. Promrat K, Lutchman G, Uwaifo GI et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004;39:188-96.
68. Lindor KD, Kowdley KV, Heathcote EJ et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004;39:770-8.
69. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000;136:734-8.
70. Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001;96:2711-17.
71. Adams LA, Zein CO, Angulo P, Lindor KD. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol 2004;99:2365-8.
72. Li Z, Yang S, Lin H et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve NAFLD. Hepatology 2003;50(2):97-106.
73. Yokohama S, Yoneda M, Haneda M et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steato-hepatitis. Hepatology 2004;40:1222-5.